← The Wire·Consumer·

Moderna shares surge 179% on melanoma therapy; revenue fell 39.9% to $1.9B

Moderna shares reportedly surged 179% on enthusiasm around a melanoma-therapy candidate, despite the company’s latest reported revenue falling 39.9% year over year to $1.9B. The setup shifts attention toward clinical validation and commercialization potential, but the existing loss profile leaves the growth reset dependent on evidence beyond the headline.

The story

The Yahoo Finance report, published August 23, says Moderna rose 179% as investors reassessed its growth prospects around a melanoma-therapy candidate. No trial readout, regulatory milestone, commercial forecast, or other supporting clinical detail was provided in the supplied material, so the magnitude and durability of the move cannot be independently grounded here.

The contrast with the company’s latest reported financial profile is material: FY 2025 revenue was $1.9B, down 39.9% year over year, while diluted EPS was $-7.26 and net margin was -145.2%. The candidate therefore sits against a business still reporting sharply lower sales and substantial losses.

The next datapoints are the candidate’s clinical efficacy and safety evidence, the timing and scope of any regulatory filings, and whether management provides a commercial path that can offset the current revenue decline. Without those details, the headline establishes investor enthusiasm but not the asset’s probability of success or its contribution to earnings.

Our read · Sun, Aug 23

The 179% MRNA surge prices a melanoma-candidate growth reset against $1.9B revenue down 39.9% and a -145.2% net margin, leaving the risk/reward mixed until clinical evidence arrives.

Why. The immediate consequence is a sharply higher evidentiary bar: Moderna’s reported $1.9B revenue was down 39.9% year over year, with a -145.2% net margin and $-7.26 diluted EPS, so a durable rerating requires the candidate to demonstrate more than headline appeal. The supplied material contains no clinical, regulatory, or commercial figures to establish a directional single-name trade, making the setup a vote rather than a conviction lean.

Both cases

The case it holdsThe bull case is that the melanoma candidate creates a new growth pathway capable of changing the market’s view of Moderna beyond its $1.9B revenue base and 39.9% year-over-year decline.
The case it breaksThe bear case is stronger on currently disclosed fundamentals, and $-7.26 diluted EPS.

What could change this view: The trade fails as a growth reset if the melanoma candidate produces weak efficacy or safety data, faces regulatory delay, or cannot translate into a credible commercial offset to declining revenue.

Moderna stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Same arc

Reports linked to this one, newest first. Automatically linked reports may cover a broader event.

Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage TrialYahoo Finance · Fri, Aug 28 · 12:16 PM ET · automatically linked
Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?Yahoo Finance · Tue, Aug 25 · 10:21 AM ET · automatically linked
Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial SuccessZeroHedge · Fri, Aug 21 · 12:46 AM ET · where the arc starts

Keep reading

More on MRNA

Moderna swings to profit as cancer-vaccine momentum gathers paceModerna cancer vaccine cuts melanoma recurrence or death by 42%Moderna revenue fell 39.9% to $1.9B in FY with -145.2% net margin

Latest on the Wire

Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Yahoo Finance as Moderna (MRNA) Soars 179% as Melanoma Therapy Candidate Rewrites Growth Story, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →